Trabectedin in Soft Tissue Sarcoma: Have We Hit the Bull’s-eye?

Rastogi, Sameer; Bakhshi, Sameer

doi:10.1200/jco.2015.65.7130

Cited by 4 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…QoL is an important consideration when considering systemic therapies for advanced soft tissue sarcomas. 13 Though the trial by Demetri et al did not report QoL, the randomized phase 3 Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma (TSAR) showed that trabectedin improves PFS without impairing QoL when compared with best supportive care. 12,20 Trabectedin unlike chemotherapy has no mucositis and hair loss, leading to better acceptance by patients.…”

Section: Discussionmentioning

confidence: 99%

“…However, this trial was criticized for not meeting its primary end-point and conspicuous absence of evaluation of quality of life (QoL). 13 Subsequently, based upon its mechanism of action it was tried in translocation-related sarcomas in various reports. 14 Kawai et al in a phase 2 randomized trial compared trabectedin with best supportive care in patients (n = 73) with translocation-related sarcoma in patients who had received multiple lines of treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Trabectedin in Advanced Sarcomas—Experience at a Tertiary Care Center and Review of Literature

Verma

Kalra

Rastogi

et al. 2021

South Asian J Cancer

Self Cite

View full text Add to dashboard Cite

Background There is sparse literature on trabectedin in advanced soft-tissue sarcomas from developing world. It would be interesting to know about use and outcomes of trabectedin in Indian patients. Method In a retrospective study, consecutive patients treated with trabectedin from 2016 to 2019 were analyzed. Patients with L-sarcomas were treated at a dose of 1.5 mg/m2, while those with translocation-related sarcomas were treated at a dose of 1.2 mg/m2 as a 24-hour infusion through peripherally inserted central catheter line. From July 2019, infusions were administered through an ambulatory elastomeric pump, while before that patients were admitted for 24 hours. We used SPSS version 23.0 for statistical calculation. Result A total of 20 patients received trabectedin with a total of 116 infusions. The median age was 46 years (range: 22–73 years). The male (n = 11, 55%) and female patients were almost equal (n = 9, 45%). Thirteen patients (65%) had Eastern Cooperative Oncology Group Performance Status 1. Majority of the patients had leiomyosarcoma (n = 8, 40%); remaining comprised of liposarcoma (3, 15%), translocation-related sarcomas excluding myxoid liposarcoma (n = 8, 40%) and others (n = 1,5%). Most common site was extremity (n = 11, 55%) followed by retroperitoneal (n = 3, 15%), visceral (n = 3, 15%), and others (n = 3,15%). Median number of previous lines received was 2 (range: 0–4). Median number of trabectedin cycles received was 4 (range: 1–17). Best response assessed was stable disease (n = 10, 50%), progressive disease (n = 6, 30%), partial response (n = 1, 5%), and not assessed in 3 patients. After a median follow-up of 19 months, median progression-free survival was 4 months. Conclusion In this heavily treated population (composed of L-sarcomas and translocation-related sarcomas) with many patients with poor performance status, the outcome with trabectedin is in synchrony with literature. However, the need of 24-hour admission might deter quality of life. Elastomeric pump seems to be a reasonable alternative to admission and can be a breakthrough in administering trabectedin, especially in developing countries.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Trabectedin in Advanced Sarcomas—Experience at a Tertiary Care Center and Review of Literature

Verma

Kalra

Rastogi

et al. 2021

South Asian J Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Trabectedin was approved in Europe in 2007 for the treatment of advanced STSs with previous anthracycline treatment failure and in the United States in 2015 for the treatment of patients with advanced leiomyosarcoma and liposarcoma with previous anthracycline treatment failure ( Nakamura and Sudo, 2022 ). It is the most studied and widely used chemotherapeutic drug for STSs, in addition to doxorubicin and ifosfamide ( Rastogi and Bakhshi, 2016 ; Dang et al, 2021 ; Le Cesne, 2022 ; Nakamura and Sudo, 2022 ; Wang et al, 2022 ). The ORR of trabectedin monotherapy for STS is 4.7%–14.8%, the median PFS is 2.8–5.9 months, and the median OS is 9.2–21.3 months ( Table 3 ).…”

Section: Efficacy Of Different Drugs In Stssmentioning

confidence: 99%

“…Although these data are similar to those of doxorubicin or ifosfamide monotherapy, recent randomized controlled studies have demonstrated that trabectedin cannot replace doxorubicin as a first-line treatment for advanced STSs ( Bui-Nguyen et al, 2015 ; Martin-Broto et al, 2016 ). In addition, several studies have demonstrated that the efficacy of trabectedin in the treatment of leiomyosarcoma and liposarcoma at the second- or above-line setting is significantly higher than in other STS subtypes (median PFS 5.1 versus 1.4 months, respectively) ( Rastogi and Bakhshi, 2016 ; Schuetze, 2021 ; Vincenzi et al, 2023 ). Therefore, it is necessary to conduct randomized controlled clinical trials in a first-line setting to compare the activity of trabectedin and doxorubicin in these histological subtypes ( Blay et al, 2014 ; Dang et al, 2021 ).…”

Section: Efficacy Of Different Drugs In Stssmentioning

confidence: 99%

Chemotherapeutic drugs for soft tissue sarcomas: a review

Tian

Yao

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Despite the low incidence of soft tissue sarcomas (STSs), hundreds of thousands of new STS cases are diagnosed annually worldwide, and approximately half of them eventually progress to advanced stages. Currently, chemotherapy is the first-line treatment for advanced STSs. There are difficulties in selecting appropriate drugs for multiline chemotherapy, or for combination treatment of different STS histological subtypes. In this study, we first comprehensively reviewed the efficacy of various chemotherapeutic drugs in the treatment of STSs, and then described the current status of sensitive drugs for different STS subtypes. anthracyclines are the most important systemic treatment for advanced STSs. Ifosfamide, trabectedin, gemcitabine, taxanes, dacarbazine, and eribulin exhibit certain activities in STSs. Vinca alkaloid agents (vindesine, vinblastine, vinorelbine, vincristine) have important therapeutic effects in specific STS subtypes, such as rhabdomyosarcoma and Ewing sarcoma family tumors, whereas their activity in other subtypes is weak. Other chemotherapeutic drugs (methotrexate, cisplatin, etoposide, pemetrexed) have weak efficacy in STSs and are rarely used. It is necessary to select specific second- or above-line chemotherapeutic drugs depending on the histological subtype. This review aims to provide a reference for the selection of chemotherapeutic drugs for multi-line therapy for patients with advanced STSs who have an increasingly long survival.

show abstract

The place of trabectedin in the treatment of soft tissue sarcoma: an umbrella review of the level one evidence

Andreeva-Gateva

Chakar

2019

Expert Opinion on Orphan Drugs

View full text Add to dashboard Cite

Trabectedin in Soft Tissue Sarcoma: Have We Hit the Bull’s-eye?

Cited by 4 publications

References 4 publications

Trabectedin in Advanced Sarcomas—Experience at a Tertiary Care Center and Review of Literature

Trabectedin in Advanced Sarcomas—Experience at a Tertiary Care Center and Review of Literature

Chemotherapeutic drugs for soft tissue sarcomas: a review

The place of trabectedin in the treatment of soft tissue sarcoma: an umbrella review of the level one evidence

Contact Info

Product

Resources

About